News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Forbes Tells the World How Medicare Bollixed Molecular Diagnostic Test Payments, Leaving Nation’s Clinical Laboratories Unpaid for Months

Columnist Steve Gottlieb, M.D., wrote that “This sort of bungling may be without precedent, even for the Medicare agency”

Since the beginning of the year, most Medicare contractors and private health insurers have not paid clinical laboratories and anatomic pathology practices for molecular diagnostic test claims coded to the 114 new molecular test CPT codes.

This unprecedented situation of labs going unpaid for more than three months has created financial turmoil and uncertainty across the medical laboratory profession. In fact, the question must be asked: Did Forbes columnist Scott Gottlieb, M.D., wake up the nation’s Medicare contractors with his column published on March 27? (more…)

Six Health IT Companies Join Forces to Develop Interoperable EHR Systems to Better Compete Against Epic’s EHR Product

CommonWell is the name of the new organization formed to create the interoperability that would enable universal access to each patient’s health care records

It was big news in the healthcare IT world when six major healthcare IT companies joined together on March 4 and announced a collaboration intended to develop electronic health record (EHR) systems that are interoperable. That is a goal that can come none too soon for clinical laboratories and anatomic pathology groups.

The collaboration will take the form of an independent nonprofit organization to be called CommonWell Health Alliance. The six companies contributing to the formation of CommonWell are:


Acquiring Pathology Laboratory Billing Expertise, McKesson Buys MED3000, Parent of PSAPath

Positioning itself to serve accountable care organizations, McKesson agrees to buy a company specializing in medical billing and physician practice management

McKesson Corporation (NYSE:MCK) announced an agreement to acquire MED3000 of Pittsburgh, Pennsylvania, earlier this week. One aspect of this transaction will be of particular interest to anatomic pathologists and pathology practice administrators.

When it closes the sale, McKesson’s ownership of MED3000 will increase its overall national market share of pathology billing and collection contracts. Dark Daily readers may recall that McKesson and MED3000 each have a sizeable number of anatomic pathology laboratories and groups as clients for their billing and collections business divisions. (more…)

Innovations in Clinical Pathology Laboratory Management at the 2011 Executive War College in New Orleans

Record crowd of pathologists and clinical laboratory managers hear from medical lab industry leaders

Dateline: New Orleans, Louisiana
—Here at the 16th annual Executive War College (EWC) on laboratory and pathology management, a crowd of record size has gathered to learn the latest trends in the clinical laboratory testing marketplace, and to hear about innovations and new management breakthroughs, as shared by top-performing medical laboratories.

As your Dark Daily editor, this is my first EWC. Readers of Dark Daily’s ebriefings ( know me from my articles on the website. I’ve learned much about clinical laboratories and anatomic pathology groups since joining The Dark Group last year. And though my editorial background includes a recent six-year stint as Editor of Health Management Technology magazine, I was nevertheless impressed by the depth of information being offered at EWC. It is why this is truly the “must attend” conference for lab managers and pathologists.

Threat to Clinical Pathology Laboratories is Payer Pre-Authorization of Genetic Tests

Health insurers want to control the rapid growth in expensive genetic and molecular assays

For many clinical laboratories and pathology groups, genetic tests and molecular diagnostic assays are the fastest-growing part of the test menu. This is true both in the increased volume of specimens for genetic tests and the growing number of such medical laboratory tests that are accepted for clinical use.

This is a bright spot for the nation’s clinical pathology laboratories. That’s because many genetic tests and molecular assays deliver significant clinical value to the physician and his or her patient—while generating ample reimbursement for the medical laboratory that performs these tests.